1. Tseng JY, Yang CY, Liang SC, Liu RS, Jiang JK, Lin CH. Dynamic changes in numbers and properties of circulating tumor cells and their potential applications.
Cancers. 2014;6(4):2369–86.
2. Böckelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol. 2015;54(1):5–16.
3. Kamiyama H, Noda H, Konishi F, Rikiyama T. Molecular biomarkers for the detection of metastatic colorectal cancer cells. World J gastroenterol. 2014;20(27):8928–38.
4. Paget, S. The distribution of secondary growth in cancer of the breast. Lancet.
1889(133):571–3.
5. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003(3):453–8.
6. Powell AA TA, Zhang H et al.. Single cell pro ling of circulating tumor cells:
transcriptional heterogeneity and diversity from breast cancer cell lines.. PLoS ONE 2012;7(5): e33788
7. Fan C, Younis A, Bookhout CE, Crockett SD. Management of Serrated Polyps of the Colon. Curr Treat Options Gastroenterol. 2018; 16(1):182–202.
8. Odze RD, Goldblum JR. Surgical Pathology of the Gl Tract, Liver, Biliary Tract and Pancreas. 2nd ed. p 634.
9. Aggarwal C, Meropol NJ, Punt CJ et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol.
2013;24(2):420–8.
10. leading-medicine-guide.de [Internet]. Heidelberg: Deutscher Verlag für Gesundheitsinformation GmbH [cited 2017 Jul 01]. Available from: https://www.leading-medicine-guide.de/zertifizierte-Zentren/Darmkrebsvorsorge.
11. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540–50.
12. Mazzocca A, Fransvea E, Dituri F, Lupo L, Antonaci S, Giannelli G. Down -regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor- stroma cross-talk and tumor progression in hepatocellular carcinoma.
Hepatology. 2010;51(2):523–34.
13. Divella R, Danielle A, Gadaleta C, Tufaro A, Venneri MT, Paradiso A, Quaranta M.
Circulating transforming growth factor-β and epidermal growth factor receptor as related to virus infection in liver carcinogenesis. Anticancer Res. 2012;32(1):141–5.
14. Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy:
selecting optimal treatments for individual patients. J Clin Oncol. 2015;33(16):1787–96.
15. Watanabe T, Wu TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344(16):1196–206.
16. Remmele W (ed). Verdauungstrakt. In: Pathologie Bd. 2. Berlin, Heidelberg: Springer;
1996.
17. Odze R, Goldblum J. Conventional adenoma, pathologic features. Surgical pathology of the Gl Tract, Liver, Biliary Tract and Pancreas. 2nd ed. Philadelphia:
Elsevier/Saunders; 2009.
18. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275–92.
19. Renz-Polster H, Krautzig S, Braun, J. Basislehrbuch Innere Medizin. 4th ed. München, Jena: Elsevier GmbH, Urban & Fischer;
20. Piper W. Innere Medizin. Heidelberg: Springer; 2007. p. 378.
21. Herold G. Innere Medizin: eine vorlesungsorientierte Darstellung. Köln: Gerd Herold;
2012.
22. Engel C, Rahner N, Schulmann K et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol.
2010;8(2):174–82.
23. Lamberti C, Mangold E, Pagenstecher C et al. Frequency of hereditary non-polyposis colorectal cancer among unselected patients with colorectal cancer in Germany.
Digestion. 2006;74(1):58–67.
24. Bosman FT Carneiro F, Hruban, RH, Theise ND., editor. Lynch Syndrome. Lyon 2010.
25. Kopetz S, Taberno J, Rosenberg R et al. Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors.
Oncologist. 2015;20(2):127–33.
26. Gray RG, Q P, Handley K et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29(35):4611–9.
27. Fritz A, Percy C, Jack A et al., editors. International Classification of Diseases for Oncology. 3rd ed. Genf: WHO; 2000.
28. Wittekind C, editor. TNM Klassifikation maligner Tumoren. 8th ed. Weinheim: Wiley-VCH; 2017.
29. Wittekind C, Compton CC, Brierley J, Sobin LH (editor s). TNM-Supplement:
Erläuterungen zur einheitlichen Anwendung. 4th ed. Weinheim: Wiley-VCH; 2014.
30. Wittekind C, Sobin LH (editors). TNM Atlas. 7th ed. New York: John Wiley & Sons;
2014.
31. Edge S, Byrd DR, Compton CC, Fritz AG, Greene F, Trotti A. AJCC Cancer staging handbook. 7th ed. Heidelberg: Springer; 2010.
32. Eickhoff A, Bechtler M, Riemann JF. Früherkennung des kolorektalen Karzinoms.
Aktuelle Vorgehensweise: Koloskopie, Stuhltest, Radiologie. best practice onkologie.
2009;4(4):4–13.
33. Gonzalez CA, Riboli E. Diet and cancer prevention: Contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. European Journal of Cancer. 2010;46(14):2555–62.
34. Halle M, Schoenberg MH. Körperliche Aktivität in der Prävention und Therapie des kolorektalen Karzinoms. Dtsch Arztebl. 2009;106(44):722–7.
Literaturverzeichnis 30 35. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). S3 -Leitlinie Kolorektales Karzinom, Langversion 1.0, AWMF Registrierungsnummer: 021-007OL.
2013.
36. Lippert H. Lehrbuch Anatomie. 6th ed. München, Jena: Elsevier GmbH, Urban &
Fischer. 2003.
37. Robert Koch-Institut, editor. Krebs in Deutschland 2005/2006. Häufigkeiten und Trends. 7th ed. Berlin 2010.
38. Schneider ARJ, Caspary WF. Diagnostik kolorektaler Karzinome. Aktueller Stand. Der Radiologe. 2003;43(2):105–12.
39. Märkl B, Kerwel TG, Jähnig HG et al. Methylene blue-assisted lymph node dissection in colon specimens: a prospective, randomized study. Am J Clin Pathol.
2008;130(6):913–9.
40. Bednarz-Knoll N, Alix-Panabières C, Pantel K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res. 2011;13(6):228.
41. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA. 2000;97(26):14608–13.
42. Fidler IJ. Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2’-deoxy- uridine. J Natl Cancer Inst. 1970;45(4):773–82.
43. Riethdorf S, Wikman H, Pantel K. Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer. 2008;123(9):1991–2006.
44. Janni W, Vogl FD, Wiedswang G et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse – a European pooled analysis. Clin Cancer Res. 2011;17(9):2967–76.
45. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer Nat Rev Cancer. 2004;4(6):448–56.
46. Schmidt T, Koch M, Antolovic D et al. Influence of two different resection techniques (conventional liver resection versus anterior approach) of liver metastases from colorectal cancer on hematogenous tumor cell dissemination – prospective randomized multicenter trial. BMC Surg. 2008;8:6.
47. Koch M, Kienle P, Sauer P et al. Hematogenous tumor cell dissemination during colonoscopy for colorectal cancer. Surg Endosc. 2004;18(4):587–91.
48. Koch M, Antolovic D, Kienle P et al. Increased detection rate and potential prognostic impact of disseminated tumor cells in patients undergoing endorectal ultrasound for rectal cancer. Int J Colorectal Dis. 2007;22(4):359–65.
49. Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C. Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol.
2010;2(6):351–65.
50. Slade MJ, Payne R, Riethdorf S et al. Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer. 2009;100(1):160–6.
51. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.
52. Rahbari NN, Bork U, Motschall E et al. Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node -negative colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(1):60–
70.
53. Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.
Clin Cancer Res. 2004;10(20):6897–904.
54. Glaves D. Correlation between circulating cancer cells and incidence of metastases. Br J Cancer. 1983;48(5):665–73.
55. Mayhew E, Glaves D. Quantitation of tumorigenic disseminating and arrested cancer cells. Br J Cancer. 1984;50(2):159–66.
56. Luzzi KJ, MacDonald IC, Schmidt EE et al. Multistep nature of metastatic inefficiency:
dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol. 1998;153(3):865–73.
57. Barbera-Guillem E, Weiss L. Cancer-cell traffic in the liver. III Lethal deformation of B16 melanoma cells in liver sinusoids. Int J Cancer. 1993;54(5):880–4.
58. Al-Mehdi AB, Tozaea K, Fisher AB, Shientag L, Lee A, Muschel RJ. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med. 2000;6(1):100–2.
59. Glinsky VV, Glinsky GV, Glinskii OV et al. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res. 2003;63(13):3805–11.
60. Glinsky GV, Glinskii AB, Berezovskaya O et al. Dual-color-coded imaging of viable circulating prostate carcinoma cells reveals genetic exchange between tumor cells in vivo, contributing to highly metastatic phenotypes. Cell Cycle. 2006;5(2):191–7.
61. Tome Y, Tsuchiya H, Hayashi K et al. In vivo gene transfer between interacting human osteosarcoma cell lines is associated with acquisition of enhanced metastatic potential.
J Cell Biochem. 2009;108(2):362–7.
62. Kallergi G, Papadaki M, Politaki E, Mavroudis D, Georgoulias V, Agelaki S. Epithe lial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011;13(3) : R59.
63. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 2012;14(1) : R15.
64. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009;11(4) : R46.patients. Breast Cancer Res. 2009;11(4): R46.
65. Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer. 2011;105(9):1338–41.
Literaturverzeichnis 32 66. Raimondi C, Gradilone A, Naso G et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat. 2011;130(2):449–55.
67. Armstrong AJ, Marengo M, Oltean S et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res. 2011;9(8):997–1007.
68. Yu M, Bardia A, Wittner BS et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339(6119):580–4.
69. Khoja L, Backen A, Sloane R et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer. 2012;106(3):508–16.
70. Tsuji T, Ibaragi S, Hu GF. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res. 2009;69(18):7135–9.
71. Wicki A LF, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin- mediated remodeling of the actin cytoskeleton. Cancer Cell. 2006;9(4):261–72.
72. Kerwel TG, Spatz J, Anthuber M, Wünsch K, Arnholdt H, Märkl B. Injecting methylene blue into the inferior mesenteric artery assures an adequate lymph node harvest and eliminates pathologist variability in nodal staging for rectal cancer. Dis Colon Rectum.
2009;52(5):935–41.
73. Märkl B, Arnholdt HM. Prognostic significance of tumor budding in gastrointestinal tumors. Expert Rev Anticancer Ther. 2011;11:1521–33.
74. Lugli A, Kirsch R, Ajioka Y et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30(9):1299–311.
75. Martin B, Schäfer E, Jakubowicz E et al. Interobserver variability in the H&E-based assessment of tumor budding in pT3/4 colon cancer: does it affect the prognostic relevance. Virchows Arch. 2018;473(2):189–97.
76. Märkl B, Wilhelms N, Anthuber M, Schenkirsch G, Schlimok G, Oruzio D. Circulating cytokeratin-positive cells and tumor budding in colorectal cancer. World J Clin O ncol.
2016;7(6):433–40.
77. Braun S, Pantel K, Müller P et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000;342(8):525–
33.
78. Pantel K, Schlimok G, Angstwurm M et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow.
J Hematother; 1994;3(3):165–73.
79. Lüllmann-Rauch R. Histologie. Stuttgart, New York: Georg Thieme; 2003.
80. Böcker W, Denk H, Heitz PU, Moch H (editors). Repetitorium Pathologie, 4th ed.
München, Jena: Elsevier GmbH, Urban & Fischer; 2008.
81. Roessner A, Pfeifer U, Müller-Hermelink HK (editors). Allgemeine Pathologie und Grundlagen der speziellen Pathologie. 11th ed. München, Jena: Elsevier GmbH, Urban
& Fischer Verlag; 2008.
82. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology.
2002;40(2):127–32.
83. Gassmann P, Enns A, Haier J. Role of tumor cell adhesion and migration in organ specific metastasis formation. Onkologie. 2004;27(6):577–82.
84. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmüller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992;340(8821):685–9.
85. Weckermann D, Polzer B, Ragg T et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol. 2009;27:1549–56.
86. Leather AJ, Gallegos NC, Kocjan G et al. Detection and enumeration of circulating tumour cells in colorectal cancer. Br J Surg. 1993;80(6):777–80.
87. Nakamori S, Kameyama M, Furukawa H et al. Genetic detection of colorectal cancer cells in circulation and lymph nodes. Dis Colon Rectum. 1997;40(10) : S29–S36.
88. Luo C, Li S. The detection and its clinical significance of cancer cells in portal vein blood of patients with colorectal carcinoma. Zhonghua Waike Zazhi 1999;37:214–5.
89. Iinuma H, Okinaga K, Adachi M et al. Detection of tumor cells in blood using CD45 magnetic cell separation followed by nested mutant allele -specific amplification of p53 and K-ras genes in patients with colorectal cancer. Int J Cancer. 2000;89(4):337–44.
90. Taniguchi T, Makino M, Suzuki K, Kaibara N. Prognostic significance of reverse transcriptase-polymerase chain reaction measurement of carcinoembryonic antigen mRNA levels in tumor drainage blood and peripheral blood of patients with colorectal carcinoma. Cancer. 2000;89:970–6.
91. Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg. 2000;232(1):58–65.
92. Etoh T, Ueo H, Inoue H et al. Clinical significance of K-Ras mutations in intraoperative tumor drainage blood from patients with colorectal carcinoma. Ann Surg Onco.
2001;8(5):407–12
93. Fujita S, Kudo N, Akasu T, Moriya Y. Detection of cytokeratin 19 and 20 mRNA in peripheral and mesenteric blood from colorectal cancer patients and their prognosis. Int J Colorectal Dis. 2001;16(3):141–6.
94. Guller U, Zajac P, Schnider A et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg. 2002;236(6):768–75.
95. Tien YW, Lee P, Wang SM, Hsu SM, Chang KJ. Simultaneous detection of colonic epithelial cells in portal venous and peripheral blood during colorectal cancer surgery.
Dis Colon Rectum 2002;45(1):23–9.
96. Akashi A, Komuta K, Haraguchi M et al. Carcinoembryonic antigen mRNA in the mesenteric vein is not a predictor of hepatic metastasis in patients with resectable colorectal cancer. Dis Colon Rectum. 2003;46(12):1653–8.
Literaturverzeichnis 34 97. Nozawa H, Watanabe T, Ohnishi T et al. Detection of cancer cells in mesenteric vein and peripheral vessels by measuring telomerase activity in patients with colorectal cancer. Surgery. 2003;134(5):791–8.
98. Sunouchi K, Machinami R, Mori M et al. Clinical impact of carcinoembryonic antigen messenger ribonucleic acid expression in tumor-draining vein blood on postoperative liver metastasis in patients with colorectal carcinoma: a prospective, cohort study. Dis Colon Rectum 2003;46(4):467–73.
99. Sadahiro S, Suzuki T, Ishikawa K et al. Detection of carcinoembryonic antigen messenger RNA-expressing cells in portal and peripheral blood during surgery does not influence relapse in colorectal cancer. Ann Surg Oncol. 2005;12(12 ):988–94.
100. Zhang XW, Yang H, Fan P, Yang L, Chen GY. Detection of micrometastasis in peripheral blood by multi-sampling in patients with colorectal cancer. World J Gastroenterol. 2005;11(3):436–8.
101. Iinuma H, Okinaga K, Egami H et al. Usefulness and clinical signifcance of quantitative real-time RT-PCR to detect isolated tumor cells in the peripheral blood and tumor drainage blood of patients with colorectal cancer. Int J Oncol. 2006;28(2):297–306.
102. Kanellos I, Zacharakis E, Kanellos D et al. Prognostic significance of CEA levels and detection of CEA mRNA in draining venous blood in patients with colorectal cancer. J Surg Oncol. 2006;94:3–8.
103. Tseng JY, Yang CY, Yang SH, Lin JK, Lin CH, Jiang JK. Circulating CD133(+)/ESA(+) cells in colorectal cancer patients. J Surg Res. 2015;199(2):362–70.
104. Pantel K, Denève E, Nocca D et al. Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 2012;58(5):936–40.
105. Bork U, Grutzmann R, Rahbari NN, Scholch S, Distler M, Reissfelder C, et al.
Prognostic relevance of minimal residual disease in colorectal cancer. World journal of gastroenterology. 2014;20(30):10296–304.
106. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.
107. Katsuno H, Zacharakis E, Aziz O et al. Does the presence of circulating tumor cells in the venous drainage of curative colorectal cancer resections determine prognosis? A meta-analysis. Ann Surg Oncol 2008;15(11):3083–91.
108. Puppa G, Senore C, Sheahan K et al. Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopy.
Histopathology 2012;61(4):562–75.
109. Cao H, Xu E, Liu H, Wan L, Lai M. Epithelial-mesenchymal transition in colorectal cancer metastasis: A system review. Pathol Res Pract. 2015;211(8):557–69.
110. Powell AA, Talasaz AAH, Zhang H et al. Single cell pro ling of circulating tumor cells:
transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE 2012;7(5): e33788.
111. Groot Koerkamp B, Rahbari NN, Büchler MW, Koch M, Weitz J. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: A meta-analysis. Ann Surg Oncol. 2013;20(7):2156–65.
112. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302–9.
113. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91.
114. Lim SH, Becker TM, Chua W et al. Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer. Cancer letters.
2014;346(1):24–33.
115. Pantel K, Brankenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008;8(5):329–40.
116. Alunni-Fabbroni M, Sandri MT. Circulating tumour cells in clinical practice: Methods of detection and possible characterization. Methods. 2010;50(4):289–97.
117. Tibbe AG, Miller MC, Terstappen LW. Statistical considerations for enumeration of circulating tumor cells. Cytometry Part A. 2007;71(3):154–62.
118. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule:
More than a carcinoma marker and adhesion molecule. Am J Pathol. 2007;171(2):386–
95.
119. Goodale D, Phay C, Brown W et al. Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer. Cytometry Part B Clin Cytom. 2009;76 (2):107–17.
120. Goodale D, Phay C, Postenka CO, Keeney M, Allan AL. Characterization of tumor cell dissemination patterns in preclinical models of cancer metastasis using flow cytometry and laser scanning cytometry. Cytometry Part A 2009;75(4):344–55.
121. Hardingham JE, Grover P, Winter M, Hewett PJ, Price TJ, Thierry B. Detection and clinical significance of circulating tumor cells in colorectal cancer – 20 Years of Progress. Mol Med 2015;21: S25–S31.
122. Hardingham JE, Kotasek D, Farmer B et al. Immunobead-PCR: a technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction. Cancer Res. 1993;53:3455–8.
123. Rahbari NN, Aigner M, Thorlund K et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer.
Gastroenterology. 2010;138(5):1714–26.
124. Lim SH, Becker TM, Chua W, Ng WL, de Souza P, Spring KJ. Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer. Journal of clinical pathology. 2014;67(10):848–53.
125. Guinney J, Dienstmann R, Wang X et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21(11):1350–6.
126. Grover PK, Cummins AG, Price TJ, Roberts-Thomson IC, Hardingham JE. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann Oncol 2014;25(8):1506–16.
Anhang 36